Makoto Ohmiya

Makoto Ohmiya is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target neurological disorders. With a total of 2 patents, his work is recognized for its potential impact on treating various cognitive impairments and mental health conditions.

Latest Patents

Ohmiya's latest patents focus on a heterocyclic acetamide compound. This compound is identified as a dopamine D1 receptor positive allosteric modulator (D1 PAM). The invention aims to provide an active ingredient for pharmaceutical compositions that can prevent and treat cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, and drug addictions. The research highlights the compound's ability to modulate dopamine D1 receptor activity, which is crucial for addressing these complex health issues.

Career Highlights

Makoto Ohmiya is currently associated with Astellas Pharma GmbH, where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to advancing medical science and improving patient outcomes through targeted therapies.

Collaborations

Ohmiya collaborates with notable colleagues such as Ryota Shiraki and Takahiko Tobe. These partnerships enhance the research and development process, fostering an environment of innovation and shared expertise.

Conclusion

Makoto Ohmiya's contributions to pharmaceutical chemistry exemplify the vital role of inventors in advancing medical science. His innovative work on heterocyclic acetamide compounds holds promise for addressing significant health challenges.

Profile summary based on public USPTO records.